1,641 results on '"Pfreundschuh, Michael"'
Search Results
2. FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials
3. Hyper-N-glycosylated SAMD14 and neurabin-I as driver autoantigens of primary central nervous system lymphoma
4. Autologous Stem Cell Transplantation for Patients with Early Progression of Follicular Lymphoma: A Follow-Up Study of 2 Randomized Trials from the German Low Grade Lymphoma Study Group
5. ESMO Consensus Conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma
6. Allogeneic stem cell transplantation for patients with relapsed or refractory T-cell lymphoma: efficacy of lymphoma-directed conditioning against advanced disease
7. LRPAP1 is a frequent proliferation-inducing antigen of BCRs of mantle cell lymphomas and can be used for specific therapeutic targeting
8. Determination of optimum vitamin D3 levels for NK cell-mediated rituximab- and obinutuzumab-dependent cellular cytotoxicity
9. Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial
10. Supplementary Figure 1 from Circulating Levels of TNF Receptor II Are Prognostic for Patients with Peripheral T-cell Non–Hodgkin Lymphoma
11. Supplementary Tables 1 - 4 from Circulating Levels of TNF Receptor II Are Prognostic for Patients with Peripheral T-cell Non–Hodgkin Lymphoma
12. Supplementary Methods and Materials, Tables 1-3 from A Functional Polymorphism in the NAD(P)H Oxidase Subunit CYBA Is Related to Gene Expression, Enzyme Activity, and Outcome in Non–Hodgkin Lymphoma
13. Impact of vincristine dose reduction on outcomes of patients with aggressive B-cell lymphoma treated with (R) - CHOP
14. Lymphocyte predominant cells detect Moraxella catarrhalis-derived antigens in nodular lymphocyte-predominant Hodgkin lymphoma
15. Matching for the MICA-129 polymorphism is beneficial in unrelated hematopoietic stem cell transplantation
16. High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial
17. Management of Diffuse Large B-Cell Lymphoma (DLBCL)
18. Human Carbonic Anhydrase XII: cDNA Cloning, Expression, and Chromosomal Localization of a Carbonic Anhydrase Gene that is Overexpressed in Some Renal Cell Cancers
19. Identification of a Meiosis-Specific Protein as a Member of the Class of Cancer/Testis Antigens
20. Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia—results of the AMLSG 11-08 trial
21. Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV
22. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes
23. A Testicular Antigen Aberrantly Expressed in Human Cancers Detected by Autologous Antibody Screening
24. Ars2‐containing bispecific, Fab‐ and IgG1‐format BAR‐bodies to target DLBCL cells
25. Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma
26. Anschriften der Herausgeber und Autoren
27. SEREX
28. B‐cell receptors of EBV‐negative Burkitt lymphoma bind modified isoforms of autoantigens
29. Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial
30. Suboptimal dosing of rituximab in male and female patients with DLBCL
31. Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial
32. Optimization of rituximab for the treatment of DLBCL: increasing the dose for elderly male patients
33. TP53 mutation and survival in aggressive B cell lymphoma
34. Author Correction: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes
35. Ars2‐containing bispecific, Fab‐ and IgG1‐format BAR‐bodies to target DLBCL cells.
36. High-resolution HLA matching in hematopoietic stem cell transplantation: a retrospective collaborative analysis
37. Diffuse large B-cell lymphoma
38. Modified BEAM with triple autologous stem cell transplantation for patients with relapsed aggressive non-Hodgkin lymphoma
39. Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML
40. Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial
41. Autoantigenic targets of B-cell receptors derived from chronic lymphocytic leukemias bind to and induce proliferation of leukemic cells
42. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma
43. Recognition of human tumors: SEREX expression cloning to identify tumour antigens
44. Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1)
45. Sumoylated HSP90 is a dominantly inherited plasma cell dyscrasias risk factor
46. Early autologous stem cell transplantation for chronic lymphocytic leukemia: long-term follow-up of the German CLL Study Group CLL3 trial
47. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial
48. High-Dose Therapy and Autologous Stem Cell Transplantation in First Relapse for Diffuse Large B Cell Lymphoma in the Rituximab Era: An Analysis Based on Data from the European Blood and Marrow Transplantation Registry
49. The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL
50. Significant dose Escalation of Idarubicin in the treatment of aggressive Non- Hodgkin Lymphoma leads to increased hematotoxicity without improvement in efficacy in comparison to standard CHOEP-14: 9-year follow up results of the CIVEP trial of the DSHNHL
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.